Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edit functionality is currently unavailable.

John David Matthews, M.D.

Co-Author

This page shows the publications co-authored by John Matthews and Maurizio Fava.
Connection Strength

2.323
  1. Matthews JD, Siefert CJ, Blais MA, Park LT, Siefert CJ, Welch CA, Dubois CM, van Nieuwenhuizen AO, Rooney KO, Seabrook RC, Durham LE, Adams HC, Fava M. A double-blind, placebo-controlled study of the impact of galantamine on anterograde memory impairment during electroconvulsive therapy. J ECT. 2013 Sep; 29(3):170-8.
    View in: PubMed
    Score: 0.610
  2. Matthews JD, Siefert C, Dording C, Denninger JW, Park L, van Nieuwenhuizen AO, Sklarsky K, Hilliker S, Homberger C, Rooney K, Fava M. An open study of aripiprazole and escitalopram for psychotic major depressive disorder. J Clin Psychopharmacol. 2009 Feb; 29(1):73-6.
    View in: PubMed
    Score: 0.444
  3. Matthews JD, Blais M, Park L, Welch C, Baity M, Murakami J, Sklarsky K, Homberger C, Fava M. The impact of galantamine on cognition and mood during electroconvulsive therapy: a pilot study. J Psychiatr Res. 2008 Jun; 42(7):526-31.
    View in: PubMed
    Score: 0.400
  4. Matthews JD, Bottonari KA, Polania LM, Mischoulon D, Dording CM, Irvin R, Fava M. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J Clin Psychiatry. 2002 Dec; 63(12):1164-70.
    View in: PubMed
    Score: 0.290
  5. Matthews JD, Fava M. Risk of suicidality in depression with serotonergic antidepressants. Ann Clin Psychiatry. 2000 Mar; 12(1):43-50.
    View in: PubMed
    Score: 0.239
  6. Sonawalla SB, Farabaugh AH, Leslie VM, Pava JA, Matthews JD, Fava M. Early drop-outs, late drop-outs and completers: differences in the continuation phase of a clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Dec; 26(7-8):1415-9.
    View in: PubMed
    Score: 0.072
  7. Perlis RH, Nierenberg AA, Alpert JE, Pava J, Matthews JD, Buchin J, Sickinger AH, Fava M. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. J Clin Psychopharmacol. 2002 Oct; 22(5):474-80.
    View in: PubMed
    Score: 0.072
  8. Farabaugh A, Mischoulon D, Yeung A, Alpert J, Matthews J, Pava J, Fava M. Predictors of stable personality disorder diagnoses in outpatients with remitted depression. J Nerv Ment Dis. 2002 Apr; 190(4):248-56.
    View in: PubMed
    Score: 0.069
  9. Sonawalla SB, Farabaugh AH, Leslie VM, Pava JA, Matthews JD, Fava M. Early drop-outs, late drop-outs and completers: differences in the continuation phase of a clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Apr; 26(3):415-9.
    View in: PubMed
    Score: 0.069
  10. Dording CM, Mischoulon D, Goodness TM, Baer L, Clain A, Stewart JW, Matthews JD, McGrath PJ, Nierenberg AA, Fava M, Papakostas GI. Psychoticism and paranoid ideation in patients with nonpsychotic major depressive disorder: prevalence, response to treatment, and impact on short- and long-term treatment outcome. CNS Spectr. 2010 Aug; 15(8):515-21.
    View in: PubMed
    Score: 0.031
  11. Dording CM, Sinicropi-Yao L, Papakostas G, Matthews JD, Nierenberg AA, Fava M, Mischoulon D. The response of psychotic-like symptoms to fluoxetine monotherapy in non-psychotic major depressive disorder. Nord J Psychiatry. 2009; 63(5):420-5.
    View in: PubMed
    Score: 0.028
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.